Form 4: CRISPR Therapeutics' Chief Medical Officer Receives Stock Options and Restricted Stock Units

Naimish Patel, Chief Medical Officer of CRISPR Therapeutics, was granted stock options for 85,000 shares and 40,000 restricted stock units on May 28, 2024.

Summary

• Naimish Patel, the Chief Medical Officer of CRISPR Therapeutics, received stock options and restricted stock units.
• On May 28, 2024, Patel was granted options to purchase 85,000 common shares at an exercise price of $54.84.
• These options vest over a period of four years, with 25% vesting on May 28, 2025, and the remaining shares vesting in 36 equal monthly installments thereafter.
• Patel also received 40,000 restricted stock units, each representing a contingent right to receive one share of CRSP common stock.
• These restricted stock units vest in four equal installments on May 28 of 2025, 2026, 2027, and 2028.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options and restricted stock units is a standard practice and generally viewed as a positive sign of aligning management's interests with shareholders.

Positives

• The grant of stock options and restricted stock units aligns the Chief Medical Officer's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the stock options and restricted stock units.

Industry Context

Executive compensation packages, including stock options and restricted stock units, are common in the biotechnology industry to attract and retain talent and align their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in biotech companies like CRISPR Therapeutics.
• Comparable companies such as Intellia Therapeutics and Editas Medicine also utilize stock options and restricted stock units as part of their executive compensation plans.
• The vesting schedules described are typical for these types of equity grants, encouraging long-term commitment.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign of aligning management's interests with the company's long-term success.
• Employees may be motivated by the fact that executives are incentivized to increase shareholder value.

Key Dates